CISPLATIN,DEXAMETHASONE & GEMCITABINE IN RELAPSED OR REFRACTORY NON HODGKIN'S

这是一项为期24小时的吉西他滨联合顺铂和地塞米松输注的I/IIa期研究。治疗周期每三周重复一次，直到达到最大疗效。吉西他滨的剂量将在三个或更多患者的队列中增加。在确定MTD之前，将继续增加吉西他滨的剂量。本研究将考虑复发性（低、中级别和选定的高级别）NHL患者进行预处理。在本研究的IIa期部分，一旦吉西他滨达到MTD，另一组患者将以低于MTD的剂量进行治疗。这种方法将提供早期的疗效视图，并将扩大我们对该方案毒性概况的了解。

This is a Phase I/IIa study of a 24-hour infusion of gemcitabine in combination with cisplatin and dexamethasone. Treatment cycles are repeated every three weeks until a maximum response is achieved. Doses of gemcitabine will be escalated in cohorts of three or more patients. Dose escalation of gemcitabine will be performed until the MTD is defined. Pretreated patients with recurrent (low, intermediate grades and selected high grade) NHL will be considered for this study. In the Phase IIa component of this study, once the MTD of gemcitabine has been reached, an additional group of patients will be treated at one dose below the MTD. This approach will give an early view of efficacy and will expand our knowledge of the toxicity profile of this regimen.